Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (281-290 of 330) with videos related to

Pageof 33
Sort By:
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Nature Medicine|June 9, 2016
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastasesJing Ni, Shakti H Ramkissoon, Shaozhen Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Nature Communications|November 19, 2023
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerPaolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Clinicogenomic characterization of inflammatory breast cancerNolan Priedigkeit, Beth Harrison, Robert Shue, et al.
JAMA Oncology|January 28, 2021
Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus StatementRachel A Freedman, Christina A Minami, Eric P Winer, et al.
Pageof 33

Showing results (281-290 of 330) with videos related to

Sort By:
Pageof 33
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Nature Medicine|June 9, 2016
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastasesJing Ni, Shakti H Ramkissoon, Shaozhen Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Nature Communications|November 19, 2023
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerPaolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Clinicogenomic characterization of inflammatory breast cancerNolan Priedigkeit, Beth Harrison, Robert Shue, et al.
JAMA Oncology|January 28, 2021
Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus StatementRachel A Freedman, Christina A Minami, Eric P Winer, et al.
Pageof 33